Aiden Corvin (Chair) , Andrew McIntosh (Co-chair) , Niamh Ryan (Discussant)
{"title":"FAMILY-BASED STUDIES IN PSYCHIATRIC GENOMICS: PROGRESS AND RELEVANCE IN 2024","authors":"Aiden Corvin (Chair) , Andrew McIntosh (Co-chair) , Niamh Ryan (Discussant)","doi":"10.1016/j.euroneuro.2024.08.079","DOIUrl":null,"url":null,"abstract":"<div><div>To our knowledge it is ten years since the last symposium on pedigree-based analyses at the WCPG. In the era of whole genome sequencing a review is timely. As costs fall, the field of psychiatric genomics is transitioning from GWAS to next generation sequencing, with power to expand our understanding of the contribution of rare mutations to genetic burden across disorders. Identified rare pathogenic variants may be more informative in understanding disease biology than the common variants of small effect that represent the majority of discovery to date.</div><div>Rare variant association studies require sample sizes an order of magnitude larger than GWAS studies. This is because rare mutations tend to be selected against in populations over a few generations. However, such mutations may be identifiable where multiple generations of the same family are available. Moreover, families do not suffer the same population stratification or other confounds that are present at a population level. This approach, with small sample numbers in a family, allows for detailed phenotypic assessment and is accessible to clinicians and researchers with limited resources who want to contribute to the field.</div><div>This symposium will provide an update on progress made in ASD, where significant understanding of the genetic architecture and disease biology is emerging, in part due to trio- and quad-based approaches. We review progress from the PGC Pedigree Sequencing Group with an example of how sequencing individual families, with small numbers of individuals can identify relevant risk mutations only identifiable with thousands of samples using case-control approaches. We describe progress in other adult disorders from the international \"Pedigree-Based Whole Genome Sequencing of Affective and Psychotic Disorders\" consortium. Finally, we review the findings from colleagues working in India who are applying pedigree-based sequencing study approaches across disorders. Across presentations we consider recruitment, and how emerging findings indicate a need for broader inclusion criteria within families than might traditionally have been considered. This session will also present new methods for investigating pedigrees in the era of whole genome sequencing.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Pages 31-32"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24002785","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
To our knowledge it is ten years since the last symposium on pedigree-based analyses at the WCPG. In the era of whole genome sequencing a review is timely. As costs fall, the field of psychiatric genomics is transitioning from GWAS to next generation sequencing, with power to expand our understanding of the contribution of rare mutations to genetic burden across disorders. Identified rare pathogenic variants may be more informative in understanding disease biology than the common variants of small effect that represent the majority of discovery to date.
Rare variant association studies require sample sizes an order of magnitude larger than GWAS studies. This is because rare mutations tend to be selected against in populations over a few generations. However, such mutations may be identifiable where multiple generations of the same family are available. Moreover, families do not suffer the same population stratification or other confounds that are present at a population level. This approach, with small sample numbers in a family, allows for detailed phenotypic assessment and is accessible to clinicians and researchers with limited resources who want to contribute to the field.
This symposium will provide an update on progress made in ASD, where significant understanding of the genetic architecture and disease biology is emerging, in part due to trio- and quad-based approaches. We review progress from the PGC Pedigree Sequencing Group with an example of how sequencing individual families, with small numbers of individuals can identify relevant risk mutations only identifiable with thousands of samples using case-control approaches. We describe progress in other adult disorders from the international "Pedigree-Based Whole Genome Sequencing of Affective and Psychotic Disorders" consortium. Finally, we review the findings from colleagues working in India who are applying pedigree-based sequencing study approaches across disorders. Across presentations we consider recruitment, and how emerging findings indicate a need for broader inclusion criteria within families than might traditionally have been considered. This session will also present new methods for investigating pedigrees in the era of whole genome sequencing.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.